Russia registering a vaccine for novel coronavirus even before beginning a Phase-3 trial and promising to begin full-scale production of the vaccine in September to make it available by November is riddled with safety and ethical issues. But virologist Dr Jacob John feels a vaccine using a recombinant adenovirus construct to ferry the synthetic genetic … Continue reading Why Russia’s rushed-up coronavirus vaccine is mired in ethical, safety landmine
Ad5-nCoV
Results of coronavirus vaccine trials call for cautious optimism
Never before have candidate vaccines been developed from scratch, tested on animals and completed early stages of human clinical trials all under six months. This is an acid test for vaccine science and development and the outcomes will have far-reaching consequences either way. With novel coronavirus continuing to spread across continents infecting over 14.7 million … Continue reading Results of coronavirus vaccine trials call for cautious optimism
Phase-2 trial: Adenovirus COVID-19 vaccine Ad5-nCoV found safe, immunogenic
Phase-2 trial using a single dose of recombinant adenovirus vaccine (Ad5-nCoV) vector carries the genetic material that codes for spike glycoprotein of novel coronavirus was found to be safe, well-tolerated, and able to generate rapid immune responses within 14 days and significant humoral and cellular immune responses within 28 days. Phase-2 trial using a single … Continue reading Phase-2 trial: Adenovirus COVID-19 vaccine Ad5-nCoV found safe, immunogenic
Why developing, manufacturing COVID-19 vaccines in India becomes important
With the pandemic raging across many countries and the demand for a safe, efficacious vaccine being huge, availability of an indigenous vaccine will mean guaranteed availability for Indians, while a significant percentage of the Oxford vaccine manufactured here will be earmarked for local consumption. India’s first indigenous COVID-19 vaccine (COVAXIN) developed by the Hyderabad-based Bharat … Continue reading Why developing, manufacturing COVID-19 vaccines in India becomes important
Phase-1 trial: Adenovirus COVID-19 vaccine found safe, induces immune responses
A phase-1 trial using a single dose of a vaccine (Ad5-nCoV) that uses a recombinant adenovirus type-5 vector that carries the genetic material that codes for spike glycoprotein of novel coronavirus was found to be safe, well-tolerated, and able to generate immune responses against the virus. A phase-1 trial using a single dose of a … Continue reading Phase-1 trial: Adenovirus COVID-19 vaccine found safe, induces immune responses
Science Chronicle 